Guselkumab Tremfya®
Guselkumab is a human IgG1λ monoclonal antibody directed against the p19 subunit of interleukin-23. The SHIKARI® Guselkumab portfolio provides two quantitative drug-measurement formats—Q-GUS and the specific mAb-based QS-GUS—plus quantitative determination of antibodies to guselkumab with S-ATGUS.
Why Guselkumab is relevant to biological-drug monitoring research
Guselkumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Guselkumab is a fully human IgG1λ monoclonal antibody that binds the p19 subunit of interleukin-23 and inhibits IL-23-mediated signalling. Source ↗
Approved Indications
EMA-authorised uses include plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease, with age and regimen depending on the indication. EMA source ↗
Steady-State Trough Exposure
FDA pharmacokinetic data provide clear regimen-specific trough references:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Three complementary research assays
Enzyme immunoassay for the quantitative determination of guselkumab in human serum and plasma, developed for concentration measurement between the Cmin and Cmax range.
Enzyme immunoassay for the specific and quantitative determination of guselkumab in human serum and plasma, developed for concentration measurement between the Cmin and Cmax range.
Enzyme immunoassay for the quantitative determination of antibodies to guselkumab in human serum and plasma, with confirmation as identified in the official product record.
Kit Specifications at a Glance
| Kit Name | Catalog Code | Type | Analyte | ELISA Format | Tests | Storage |
|---|---|---|---|---|---|---|
| SHIKARI® Q-GUS | GUS-FD-TRE | Drug-Level Kit | Guselkumab | ELISA | 96 | 2–8°C |
| SHIKARI® QS-GUS | GUS-SPEC-GUS | Specific Drug-Level Kit | Guselkumab | ELISA | 96 | 2–8°C |
| SHIKARI® S-ATGUS | GUS-QNS-TRE | Quantitative ADA Kit | Antibodies to guselkumab | ELISA | 96 | 2–8°C |
* Store at +4°C and refer to the current protocol supplied with the kit. All three official records list human species reactivity and 85–115% spike recovery. Specifications were verified against the official product records.
Which kit fits your research question?
Choose between the two quantitative drug-measurement formats and the separate anti-drug-antibody assay according to the study design.
Guselkumab Literature and Product-Use Records
Ready to order, or need technical guidance?
Matrix Biotek can help identify the appropriate Guselkumab assay and prepare regional quotation and delivery information. SHIKARI® products are developed and manufactured in Ankara and supported through our European headquarters in Barcelona.